Literature DB >> 3709634

Pharmacokinetics of methysergide and its metabolite methylergometrine in man.

U Bredberg, G S Eyjolfsdottir, L Paalzow, P Tfelt-Hansen, V Tfelt-Hansen.   

Abstract

Five healthy men were given 1.0 mg methysergide maleate intravenously and 2.7 mg methysergide maleate orally in a cross-over study. The systemic availability of methysergide was only 13%, most probably due to a high degree of first-pass metabolism to methylergometrine. We also found evidence of extrahepatic clearance of methysergide. After oral administration the plasma concentrations of the metabolite were considerably higher than those of the parent drug and the area under the plasma concentration curve (AUC) for methylergometrine was more than ten times greater than for methysergide. Our findings may be relevant to the treatment of migraine if methylergometrine contributes to the effect of methysergide. Methylergometrine had a significantly longer elimination half-life than methysergide (223 +/- 43 min vs 62.0 +/- 8.3 min and 174 +/- 35 min vs 44.8 +/- 8.1 min in the oral and intravenous studies respectively).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709634     DOI: 10.1007/bf00614199

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Human plasma levels of some anti-migraine drugs.

Authors:  J Meier; E Schreier
Journal:  Headache       Date:  1976-07       Impact factor: 5.887

2.  Metabolism of methysergide and retroperitoneal fibrosis.

Authors:  J R Bianchine; A P Friedman
Journal:  Arch Intern Med       Date:  1970-08

3.  Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection.

Authors:  P O Edlund
Journal:  J Chromatogr       Date:  1981-11-13

4.  Metabolite pharmacokinetics: the area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites.

Authors:  K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1981-08
  4 in total
  20 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 2.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

Review 3.  [Coronary spasm--a clinically relevant problem?].

Authors:  W Auch-Schwelk
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

4.  Arterial diameter during central volume depletion in humans.

Authors:  H K Iversen; P Madsen; S Matzen; N H Secher
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1995

5.  Structural determinants of 5-HT2B receptor activation and biased agonism.

Authors:  John D McCorvy; Daniel Wacker; Sheng Wang; Bemnat Agegnehu; Jing Liu; Katherine Lansu; Alexandra R Tribo; Reid H J Olsen; Tao Che; Jian Jin; Bryan L Roth
Journal:  Nat Struct Mol Biol       Date:  2018-08-20       Impact factor: 15.369

Review 6.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 7.  Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

8.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Michael H Baumann; Richard B Rothman
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 9.  5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives.

Authors:  J R Fozard; H O Kalkman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

10.  Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study.

Authors:  Alfredo I Niño-Maldonado; Gary Caballero-García; Wilfrido Mercado-Bochero; Fernando Rico-Villademoros; Elena P Calandre
Journal:  Head Face Med       Date:  2009-11-08       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.